Table 4.
Annual percent changes in lymphoid neoplasm incidence rates* by subtype, race, and sex, 12 SEER registries, 1992-2001
|
Men
|
Women
|
||||||
|---|---|---|---|---|---|---|---|
| Lymphoid neoplasm subtype | Total† | White | Black | Asian | White | Black | Asian |
| Lymphoid neoplasms, total | –0.50‡ | –0.84§ | –1.84 | –0.33 | 0.08 | 0.14 | 1.39 |
| B-cell lymphoid neoplasms, total | 0.51‡ | 0.23 | –1.25 | 0.86 | 1.01§ | 0.43 | 2.11‡ |
| DLBCL | –0.46§ | –0.73§ | –2.28 | –1.99 | 0.19 | 1.27 | 1.75 |
| Marginal zone lymphoma | 21.31§ | 21.36§ | –∥ | 18.14‡ | 22.17§ | –∥ | 17.49‡ |
| Follicular lymphoma | 0.51 | 0.10 | –1.31 | 4.48 | 1.24‡ | 0.19 | –0.05 |
| CLL/SLL | –2.67§ | –2.20§ | –3.68‡ | –0.76 | –3.11§ | –1.78 | –8.99§ |
| Mantle cell lymphoma | 8.08§ | 12.21§ | 5.74 | 13.67‡ | 2.02 | –∥ | –∥ |
| Burkitt lymphoma/leukemia | 8.36§ | 5.47‡ | 7.95 | 17.85§ | 15.61§ | –∥ | 11.48 |
| Plasma cell neoplasms | –0.73 | –0.78 | –1.86 | –2.06 | –0.67 | –1.59 | 2.79 |
| Hairy cell leukemia | –1.84 | –2.77‡ | –∥ | –1.13 | 2.35 | –∥ | –∥ |
| Lymphoplasmacytic lymphoma | 4.42‡ | 5.30‡ | 5.41 | 5.25 | 2.86 | –5.31 | –∥ |
| Waldenström macroglobulinemia | –0.21 | 1.01 | –3.25 | –6.51 | –1.11 | –∥ | –∥ |
| B-cell lymphoid neoplasms, NOS | 1.64 | 1.36 | 3.48 | –1.34 | 2.13 | 7.53 | 0.92 |
| T/NK-cell lymphoid neoplasms, total | 3.80§ | 3.45§ | 1.09 | 3.73‡ | 4.32 | 6.74‡ | 1.05 |
| Mycosis fungoides/Sézary syndrome | 1.11 | 1.16 | –1.73 | –5.20 | 1.32 | 6.08 | –2.09 |
| Peripheral T-cell lymphoma | 6.55§ | 6.21§ | 0.77 | 5.09 | 6.15‡ | 13.53‡ | 2.24 |
| T/NK-cell lymphoid neoplasms, NOS | 3.26‡ | 3.01 | 4.46 | 7.32 | 4.52 | –0.69 | 3.05 |
| Lymphoblastic leukemia/lymphoma | 0.08 | –0.82 | –4.03 | 0.94 | 2.24 | 2.17 | –1.90 |
| Prolymphocytic leukemia | 3.93 | 0.73 | –∥ | –∥ | 3.26 | –∥ | –∥ |
| Hodgkin lymphoma | –0.49 | –0.27 | 1.18 | –0.63 | –0.52 | –3.12 | 6.61‡ |
| Classical Hodgkin lymphoma | –0.60‡ | –0.41 | 0.94 | –0.41 | –0.53 | –3.89‡ | 7.00‡ |
| Nodular sclerosis | 0.17 | 0.66 | 3.67 | 0.67 | –0.32 | –2.65 | 5.64 |
| Mixed cellularity/lymphocyte depleted | –6.02§ | –6.09§ | –6.54‡ | –8.15 | –4.09‡ | –11.27 | 2.76 |
| Classical Hodgkin lymphoma, NOS | 3.52‡ | 3.96‡ | 6.24 | –∥ | 2.89 | –1.05 | –∥ |
| Nodular lymphocyte predominant Hodgkin lymphoma | 3.20 | 4.00 | 5.06 | –∥ | 0.80 | 4.61 | –∥ |
| Unknown type lymphoid neoplasms | –12.41§ | –13.86§ | –11.00§ | –14.28§ | –10.78§ | –6.82‡ | –10.17§ |
APC indicates annual percent change; other abbreviations are explained in Table 1.
*
All incidence rates are age adjusted to the 2000 United States population
†
The total APC is based on the incidence of lymphoid neoplasms among individuals of all races (whites, blacks, Asians, and other or unknown race)
‡
P < .05
§
P < .01
∥
Calculation of the APC was precluded by at least one annual rate of zero